Business Wire

ZTE Launches Axon for Global Market at IFA 2015

4.9.2015 06:00 | Business Wire

Del

ZTE, a leading global mobile device maker, today announced the launch of the international version of its new global flagship smartphone, ZTE Axon Elite, at IFA 2015. The ZTE Axon Elite is set to go on sale in markets across Europe, Latin America and the Asia-Pacific in the coming months.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150903005938/en/

ZTE Axon Elite (Photo: Business Wire)

ZTE Axon Elite (Photo: Business Wire)

“After two successful launches in the U.S. and China, we are delighted to continue the global rollout of Axon with this latest version for Europe, Latin America and the Asia-Pacific,” said Adam Zeng, CEO, ZTE Mobile Devices. “Axon is the start of big and bold things for ZTE, and we will continue to evolve our Axon flagship line to align with our global strategies.”

Axon is a new line of high-end smartphones from ZTE, competitively positioned as premium, flagship devices, designed to meet the needs of global customers. The Axon Elite will first go on sale online via eBay for France, Germany, Italy, Spain and the United Kingdom on 24 September, priced at 419.99 Euros (or 299.99 GBP). Starting from the end of September, ZTE will partner with MediaMarkt to sell the Axon Elite on the open market in Germany, the device’s first offline launch, and will continue rollout of the device in Spain, France, Turkey, Mexico, Singapore, Malaysia, Thailand, Hong Kong, Russia and the Philippines.

The Axon Elite can be unlocked with three different biometric authentication options – fingerprint, voice control and eye-scan. Additionally, it comes with 32GB of internal storage, which can be expanded to an extra 128GB with a microSD card, and features Corning’s Antimicrobial Gorilla Glass.

ZTE’s Axon phones combine the right hardware and software to offer the best sound quality, camera functionality, and all-round smooth performance. This includes ‘dual track’ high fidelity sound recording and playback, as well as dual rear-cameras that capture high resolution images and videos.

ZTE will be showcasing the Axon Elite at Hall 25, Stand 105 at the Berlin ExpoCenter City.

ZTE Axon Elite – eBay links (add to ‘Watch list’ – available for purchase from 24 September)

France: http://www.ebay.fr/itm/301725125012

Germany: http://www.ebay.de/itm/141758555595

Italy: http://www.ebay.it/itm/291550442188

Spain: http://www.ebay.es/itm/221866281521

United Kingdom: http://www.ebay.co.uk/itm/331639864316

Global: http://www.ebay.com/itm/271969968508 (excluding U.S. and Canada)

About ZTE Mobile Devices

ZTE Mobile Devices is a division of ZTE Corporation, a global telecommunications equipment, networks and mobile devices company headquartered in Shenzhen, China. ZTE is a publicly traded company listed on the Hong Kong and Shenzhen stock exchanges.

ZTE is one of the global leaders in the mobile handset manufacturing industry in the world, offering a complete range of mobile devices, including mobile phones, tablets, mobile broadband modems and hotspots and family desktop integration terminals.

ZTE has strategic partnerships with 47 of the world’s top 50 carriers. ZTE is also the only company globally that has been ranked inside the Top-3 by WIPO (World Intellectual Property Organization) for the past 5 years (2010-2014) for patent filings. For more information, please visit: www.ztedevice.com.

 

ZTE Axon Elite

Network  

GSM 850/900/1800/1900,
EVDO BC0
WCDMA: Band 1/2/5/8;
TD-LTE: Band 38/40/41;
FDD-LTE: Band 1/3/7/8/12/17/20

Platform   Qualcomm Snapdragon 810 processor with Adreno™ 430 GPU
OS   MiFavor 3.2 (Android OS 5.0.2)
Dimensions   154mm x 75mm x 9.3mm
Colors   Ion Gold
Screen  

5.5" CGS (Continuous Grain Silicon) TFT LCD, 2.5D curved display.
LCD Resolution: 1920 x 1080 FHD, PPI 401
Corning Antimicrobial Gorilla Glass

Camera  

Rear-Facing Camera: Dual lens 13MP, 2MP, dual LED Flash, 4K HD resolution
Front-Facing Camera: 8MP, 84 degree wide-angle, 1080p HD resolution
Video Capture: 4K HD resolution at 30 FPS

Audio  

Hi-Fi Audio Chipset: AKM 4961
Microphone: 2- mic noise suppression

Security   Fingerprint scanner (five finger records), Visit Mode, TrustZone, EyePrint ID™, Voice Unlocking
Battery   3000mAh, Quick Charge™
Memory   3GB LP DDR4 RAM + 32GB eMMC ROM, supports 128GB TF card
Interface   3.5mm Earphone port, supports quick charge 5pin Micro USB,

Dual-SIM 4FF, SD card

Features   GPS/Beidu /Glonass/BT 4.0/WIFI 2.4G & 5G, 802.11 a/b/g/n /ac WIFI Direct

Accelerometer/Proximity/Light/ Electronic compass / Hall sensors, driver assistant

Contact information

ZTE Corporation
Eva Chen, +86 21 68897511
chen.zhengying@zte.com.cn
or
Waggener Edstrom Communications
Laura Liu, +86 10 59001242
laural@waggeneredstrom.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 07:08Pressemelding

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom